1. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer;Kupperman;Cancer Res,2010
2. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells;Chauhan;Clin Cancer Res,2011
3. Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 phase-1 studies;Gupta;ASH Annual Meeting Abstracts,2011
4. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): a phase I study;Kumar;J Clin Oncol,2012
5. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM);Lonial;J Clin Oncol,2012